Funding profile · Synthetic biology tools

Ansa Biotechnologies

Four Regulation D offerings since 2020 record $124.2 million actually sold. The announced lifetime total runs about $12 million higher, and the gap is money committed but not yet taken in.

$124.2MSold across four Form D offerings, 2020 to 2025
$68.0MSeries A sold, 28 investors, May 2022 amendment
$46.4MSeries B sold of $56.9M offered, Dec 2025 amendment
$1.22MNSF SBIR Phase I and II, non-dilutive

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Dec 2018 Pre-seed Not disclosed separately Fifty Years (lead) Release
Jun to Sep 2020 Seed $7.9M announced; $4,734,242 sold of $9,213,151 Horizons Ventures (lead), Mubadala Capital, Humboldt Fund; 24 on the filing Form D
Oct 2021 Bridge, equity and debt $5,000,000 of $5,000,000 7 investors, not named Form D
Mar to May 2022 Series A $68M announced; $67,999,951 sold of $76,671,201 Northpond Ventures (lead), RA Capital, Blue Water, Altitude, Fiscus, PEAK6, Carbon Silicon, Codon, plus seed holders Form D
Jun 2024 to Dec 2025 Series B $54.4M announced; $46,449,665 sold of $56,934,922 Cerberus Ventures (lead), Fall Line Capital, AIM13, Black Opal; 41 on the filing Filing under announcement
2019 to 2023 NSF SBIR Phase I and II $1,219,682 National Science Foundation Public record

What the filings show

Form D/A · filed Dec 10, 2025

Original
Form D filed Oct 2, 2025
First sale
Jun 28, 2024
Offered
$56,934,922 equity
Sold
$46,449,665 · $10,485,257 remaining
Investors
41 · average about $1,133,000
Exemption
Rule 506(b)
Related persons
Jason T. Gammack, Daniel Lin-Arlow (officer and director); Sebastian Palluk (officer); Yanniv Dorone, Matthew McManus, Chenny Zhang (directors)
Filing
SEC EDGAR, CIK 0001816722

Form D/A · filed May 5, 2022

Original
Form D filed Apr 14, 2022
First sale
Mar 18, 2022
Offered
$76,671,201 equity and debt
Sold
$67,999,951 · $8,671,250 remaining
Investors
28 · average about $2,429,000
Exemption
Rule 506(b)
Related persons
Daniel Lin-Arlow, Sebastian Palluk (officer and director); Lily Li (director)
Filing
SEC EDGAR, CIK 0001816722

Form D · filed Oct 15, 2021

First sale
Oct 8, 2021
Offered
$5,000,000 equity and debt
Sold
$5,000,000 · nothing remaining
Investors
7 · average about $714,000
Exemption
Rule 506(b)
Related persons
Daniel Lin-Arlow, Sebastian Palluk
Filing
SEC EDGAR, CIK 0001816722

Form D · filed Jul 9, 2020

First sale
Jun 24, 2020
Offered
$9,213,151 equity, debt and other
Sold
$4,734,242 · $4,478,909 remaining
Investors
24 · average about $197,000
Exemption
Rule 506(b)
Related persons
Daniel Hillel Lin-Arlow, Sebastian Palluk
Filing
SEC EDGAR, CIK 0001816722, Berkeley address

Reading the filings

  1. The Series A landed as announced.The release said $68 million. The May 2022 amendment reports $67,999,951 sold from 28 investors, about $2.43 million each. Announcement and filing agree to within $49.
  2. The Series B did not.The October 1, 2025 headline says $54.4 million. The same release says $45.2 million closed plus $9.2 million committed. The Form D filed a day later reports $45,199,665 sold of $55,477,037 offered. The December amendment adds two investors and $1,250,000, reaching $46,449,665, and leaves $10,485,257 unsold. A company release three weeks later called the round $54.5 million.
  3. The clock started fifteen months early.Both Series B filings give a first sale of June 28, 2024 and mark the offering as running more than a year. A Form D is due within fifteen days of first sale; the first arrived October 2, 2025. Either the round filled quietly for a year before the announcement, or an earlier instrument was folded in and dated from its own first sale.
  4. Public totals count money not yet in.GenomeWeb put the lifetime total at “at least $136.4 million” and Fierce Pharma at “more than $134 million”. The filings as sold give $4,734,242 plus $5,000,000 plus $67,999,951 plus $46,449,665, or $124,183,858. The gap is the $9.2 million of commitments plus seed money sold after the 2020 filing with no amendment on record.
  5. A $5 million bridge sits before the Series A.October 2021: exactly $5,000,000 offered and sold to seven investors, equity and debt, first sale October 8. The Series A first sale followed five months later. That is the shape of a convertible bridge from existing holders.
  6. The board turned over with the money.2020 and 2021 list only the founders. 2022 adds Lily Li, then a Northpond principal. By 2025 Li is gone, Palluk is an officer but no longer a director, and Chenny Zhang of Cerberus, Yanniv Dorone of Fall Line and Matthew McManus are directors. The filings do not state McManus’s affiliation, and none was found.

Commercial signals

Signal Detail Source type
Distribution IDT, a Danaher company, began offering Ansa Clonal DNA and XL Clonal DNA on Jan 14, 2026. Terms not disclosed. Partner-stated
Pricing Extra large clonal DNA from about 38 down to 28 cents per base pair. A 50 kb construct at 28 cents is roughly $14,000. Company-stated
Guarantee Complete order on time or free, for orders classed as guaranteed, which the CEO put above 90 percent. Not offered through resellers. Company-stated
Capacity Three production devices, a second generation synthesizer in development, 56 employees, reported December 2025. Independent
Named users Allen Institute Seattle Hub, Applied StemCell, the George Church laboratory, DSM-Firmenich through IDT. Company and partner
Revenue Never disclosed. Not found

What to watch

  • An amended Form D closing the $10,485,257 still unsold.
  • Whether the $9.2 million of commitments converts into sold securities.
  • Any Series C filing, and whether it is filed on time.
  • First disclosure of revenue or on-time performance against the guarantee.

The Ansa Biotechnologies story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Culture Biosciences: Shared investor: Northpond Ventures. A cloud lab that ran other companies’ fermentation for them, now selling the bioreactor itself through Cytiva
  • Helix Nanotechnologies: Shared investor: Cerberus Ventures. An mRNA company that started on cancer, turned to COVID-19 in one week of March 2020, and took a single vaccine candidate into a first human study in Australia
  • Asher Bio: Shared investor: Ra Capital. A South San Francisco company rebuilding interleukin-2 so it reaches only the killer T cells that attack tumors
  • YourChoice Therapeutics: Shared investor: Ra Capital. A San Francisco company developing YCT-529, an oral non-hormonal male contraceptive licensed from the University of Minnesota

Sources

  1. Public recordForm D, Ansa Biotechnologies, Inc.SEC · Jul 9, 2020
  2. Public recordForm D, Ansa Biotechnologies, Inc.SEC · Oct 15, 2021
  3. Public recordForm D and Form D/ASEC · Apr 14 and May 5, 2022
  4. Public recordForm D and Form D/ASEC · Oct 2 and Dec 10, 2025
  5. Public recordNSF SBIR awards 1914354 and 2036532NSF · 2019 to 2023
  6. IndependentAnsa Raises $54.4M in Series B Financing RoundGenomeWeb · Oct 1, 2025
  7. IndependentAnsa snares $54.4M in series B financingFierce Pharma · Oct 2, 2025
  8. IndependentAnsa Targets Nucleic Acid Synthesis Market With Ultra-Long Clonal DNAGenomeWeb · Dec 17, 2025
  9. CompanyAnsa Secures $54.4 Million in Series B FinancingBusiness Wire · Oct 1, 2025
  10. CompanyAnsa Raises $9.2 Million in Combined Seed and Pre-Seed FinancingBusiness Wire · Sep 14, 2020
  11. PartnerIDT Expands Synthetic Biology Portfolio with Ansa Clonal DNAIDT · Jan 14, 2026

Compiled from SEC, NSF and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Ansa Biotechnologies. This page is not an offer to sell or a recommendation to buy any security.